Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AMNEAL PHARMACEUTICALS, INC. (AMRX) vs Indivior Pharmaceuticals Inc. (INDV)

AMNEAL PHARMACEUTICALS, INC. and Indivior Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. AMNEAL PHARMACEUTICALS, INC. is the larger, with a market value of $6.3B against $4.3B — 1.5× the size. Indivior Pharmaceuticals Inc. trades at the lower P/E: 12.4× against 39.5×. Indivior Pharmaceuticals Inc. grew revenue faster over the last twelve months: 13.5% against 9.28%. Indivior Pharmaceuticals Inc. has the higher net margin (26.8% vs 5.05%) and the higher return on invested capital (460.5% vs 11.1%). Across the 20 metrics below, Indivior Pharmaceuticals Inc. leads on 15 and AMNEAL PHARMACEUTICALS, INC. on 5.

Valuation

Metric AMRX INDV Drug Manufacturers Specialty & Generic median
P/E 39.54 12.40 20.14
P/S 2.02 3.20 2.25
P/B 191.09 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 13.30 10.43 12.29
EV/Sales 2.84 3.42 2.56
Earnings yield 2.53% 8.07% (2.99%)
Free cash flow yield (0.18%) (2.65%) 0.00%

Profitability

Metric AMRX INDV Drug Manufacturers Specialty & Generic median
Gross margin 39.32% 81.97% 53.94%
Operating margin 14.56% 31.56% 0.00%
Net margin 5.05% 26.75% 0.00%
Free cash flow margin (0.37%) (8.34%) 0.00%
Return on equity (395.84%) (153.12%) (0.40%)
Return on assets 4.37% 26.52% (3.32%)
Return on invested capital 11.05% 460.53% 0.00%

Growth

Metric AMRX INDV Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 9.28% 13.47% 10.01%
EPS growth (last fiscal year) 157.89% 3,017.87% —
Revenue growth, 5-year CAGR 8.66% 13.88% 6.74%
Net income growth, 5-year CAGR (4.57%) 0.00% 0.00%

Health

Metric AMRX INDV Drug Manufacturers Specialty & Generic median
Debt to equity 80.86 (2.34) 0.05
Current ratio 2.20 0.84 2.31
Net debt to EBITDA 3.62 0.44 0.85

Dividend

Metric AMRX INDV Drug Manufacturers Specialty & Generic median
Dividend yield 0.27% — 1.70%
Payout ratio 0.00 — 0.00

Size

Metric AMRX INDV Drug Manufacturers Specialty & Generic median
Market cap 6.32b 4.25b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack